[go: up one dir, main page]

GB201918338D0 - Method of suppressing cancer by RNA m6A methyltransferase mettl16 inhibitors - Google Patents

Method of suppressing cancer by RNA m6A methyltransferase mettl16 inhibitors

Info

Publication number
GB201918338D0
GB201918338D0 GBGB1918338.3A GB201918338A GB201918338D0 GB 201918338 D0 GB201918338 D0 GB 201918338D0 GB 201918338 A GB201918338 A GB 201918338A GB 201918338 D0 GB201918338 D0 GB 201918338D0
Authority
GB
United Kingdom
Prior art keywords
mettl16
methyltransferase
rna
inhibitors
suppressing cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1918338.3A
Other versions
GB2589912A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemestmed Ltd
Original Assignee
Chemestmed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemestmed Ltd filed Critical Chemestmed Ltd
Priority to GB1918338.3A priority Critical patent/GB2589912A/en
Publication of GB201918338D0 publication Critical patent/GB201918338D0/en
Priority to PCT/EP2020/085872 priority patent/WO2021116477A1/en
Publication of GB2589912A publication Critical patent/GB2589912A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1918338.3A 2019-12-12 2019-12-12 Method of suppressing cancer by RNA m6A methyltransferase mettl16 inhibitors Withdrawn GB2589912A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB1918338.3A GB2589912A (en) 2019-12-12 2019-12-12 Method of suppressing cancer by RNA m6A methyltransferase mettl16 inhibitors
PCT/EP2020/085872 WO2021116477A1 (en) 2019-12-12 2020-12-12 METHOD OF SUPPRESSING CANCER BY RNA m6A METHYLTRANSFERASE METTL16 INHIBITORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1918338.3A GB2589912A (en) 2019-12-12 2019-12-12 Method of suppressing cancer by RNA m6A methyltransferase mettl16 inhibitors

Publications (2)

Publication Number Publication Date
GB201918338D0 true GB201918338D0 (en) 2020-01-29
GB2589912A GB2589912A (en) 2021-06-16

Family

ID=69186633

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1918338.3A Withdrawn GB2589912A (en) 2019-12-12 2019-12-12 Method of suppressing cancer by RNA m6A methyltransferase mettl16 inhibitors

Country Status (2)

Country Link
GB (1) GB2589912A (en)
WO (1) WO2021116477A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116113712A (en) * 2020-07-17 2023-05-12 欧洲分子生物学实验室 Prognostic Biomarkers for Cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3512236B2 (en) * 1994-06-29 2004-03-29 杏林製薬株式会社 Pyrazolopyridine oxoalkylene acid derivatives and their production
US5767134A (en) * 1997-05-15 1998-06-16 Vion Pharmaceuticals, Inc. Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP
US5942527A (en) * 1997-08-27 1999-08-24 K & K Biosciences, Inc. Hydrazones, hydrazines, semicarbazones and thiosemicarbazones derived from pyridyl ketones as anticonvulsant drugs and excitatory amino acid antagonists
AP2006003756A0 (en) * 2004-03-05 2006-10-31 He Regents Of The University O Anti-parasitic compounds and methods of their use
CN102105470B (en) * 2008-06-17 2014-06-04 韩国巴斯德研究所 Pyridopyrimidine compounds as anti-tuberculosis drugs
US9622993B2 (en) * 2014-04-07 2017-04-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. Thiosemicarbazones inhibitors of lysophosphatidic acid acyltransferase and uses thereof
WO2017030983A1 (en) * 2015-08-14 2017-02-23 Mateon Therapeutics, Inc. Compositions and methods for inhibition of cathepsins
US20200129596A1 (en) 2017-03-13 2020-04-30 City Of Hope m6A mRNA MODIFICATION IN CANCER TREATMENT
CN108250058B (en) * 2018-01-19 2022-02-11 上海怡立舍生物技术有限公司 PPAR agonists and their use in the treatment of senile dementia and other diseases
CN109796497B (en) * 2019-01-16 2020-12-22 广西师范大学 A kind of bismuth compound using 2-acetyl-3-ethylpyrazine thiosemicarbazide as ligand and its synthesis method
CN109897071A (en) * 2019-03-28 2019-06-18 广西师范大学 It is a kind of using 2- pyridine carboxaldehyde thiosemicarbazones as the platinum complex of ligand and its synthetic method and application

Also Published As

Publication number Publication date
GB2589912A (en) 2021-06-16
WO2021116477A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
SG11202105109PA (en) Method for detection of rna
HUE061482T2 (en) Method of synthesis
EP3585892B8 (en) Methods for purification of messenger rna
IL288022A (en) Methods for purification of messenger rna
HUE059025T2 (en) Methods for purification of messenger rna
EP4017489A4 (en) Method of treating kras-associated cancers
GB201903056D0 (en) Method of oligonucleotide synthesis
IL288707A (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer
GB2590998B (en) Method of wellbore operations
GB202103256D0 (en) Method for silencing genes
IL289032A (en) Method for decreasing adverse-effects of interferon
EP3874055C0 (en) Enzymatic method for preparation of udp-galactose
IL324840A (en) Method for stabilizing rna
IL289811A (en) Method of treating cancer
IL288665A (en) Methods of treating cancer using prmt5 inhibitors
GB202210325D0 (en) Methods
GB202205881D0 (en) Methods
SG11202101297UA (en) Method for culturing cancer tissue or tissue analogous to cancer tissue
EP4072561A4 (en) Methods of treating cancer
EP3784792C0 (en) Enzymatic method for preparation of gdp-fucose
SG11202107017TA (en) Methods of treating cancer
GB201918338D0 (en) Method of suppressing cancer by RNA m6A methyltransferase mettl16 inhibitors
GB201903055D0 (en) Method of oligonucleaotide synthesis
EP4067489A4 (en) Method for reducing toxicity of antisense nucleic acids
GB201915856D0 (en) Method of printing

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)